The treatment of desmoid tumors: a stepwise clinical approach, Annals of Oncology, vol.23, issue.suppl 10, pp.158-166 ,
DOI : 10.1093/annonc/mds298
Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines, J Natl Compr Canc Netw, vol.10, pp.951-960, 2012. ,
Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG), Annals of Oncology, vol.23, issue.1, pp.182-186, 2012. ,
DOI : 10.1093/annonc/mdr051
Successful Chemotherapeutic Modality of Doxorubicin Plus Dacarbazine for the Treatment of Desmoid Tumors in Association With Familial Adenomatous Polyposis, Journal of Clinical Oncology, vol.24, issue.1, pp.102-105, 2006. ,
DOI : 10.1200/JCO.2005.02.1923
High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors, Cancer, vol.27, issue.3, pp.612-620, 2004. ,
DOI : 10.1002/cncr.11937
Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis, Clinical Cancer Research, vol.17, issue.12, pp.4082-4090, 2011. ,
DOI : 10.1158/1078-0432.CCR-10-3322
Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up, Annals of Oncology, vol.22, issue.2, pp.452-457, 2011. ,
DOI : 10.1093/annonc/mdq341
Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial, Clinical Cancer Research, vol.16, issue.19, pp.4884-4891, 2010. ,
DOI : 10.1158/1078-0432.CCR-10-1177
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor, Journal of Clinical Oncology, vol.21, issue.23, pp.4342-4349, 2003. ,
DOI : 10.1200/JCO.2003.04.190
Mutation or Amplification, Journal of Clinical Oncology, vol.29, issue.21, pp.2904-2909, 2011. ,
DOI : 10.1200/JCO.2010.33.9275
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors, Annals of Oncology, vol.23, issue.9, pp.2409-2414, 2012. ,
DOI : 10.1093/annonc/mdr626
Response of a KIT-Positive Extra-Abdominal Fibromatosis to Imatinib Mesylate and KIT Genetic Analysis, JNCI Journal of the National Cancer Institute, vol.98, issue.8, pp.562-563, 2006. ,
DOI : 10.1093/jnci/djj137
mutational status, Journal of Neurosurgery, vol.104, issue.5, pp.749-756, 2006. ,
DOI : 10.3171/jns.2006.104.5.749
Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis, British Journal of Cancer, vol.103, issue.4, pp.482-485, 2010. ,
DOI : 10.1093/jnci/djj417
Prognostic Factors Influencing Progression-Free Survival Determined From a Series of Sporadic Desmoid Tumors: A Wait-and-See Policy According to Tumor Presentation, Journal of Clinical Oncology, vol.29, issue.26, pp.3553-3558, 2011. ,
DOI : 10.1200/JCO.2010.33.5489
A Prognostic Nomogram for Prediction of Recurrence in Desmoid Fibromatosis, Annals of Surgery, vol.258, issue.2, pp.347-353, 2013. ,
DOI : 10.1097/SLA.0b013e31828c8a30
Targeted KRAS Mutation Assessment on Patient Tumor Histologic Material in Real Time Diagnostics, PLoS ONE, vol.26, issue.11, pp.1471-2407632, 2009. ,
DOI : 10.1371/journal.pone.0007746.t005
MIQE pr??cis: Practical implementation of minimum standard guidelines for fluorescence-based quantitative real-time PCR experiments, BMC Molecular Biology, vol.11, issue.1, p.74, 2010. ,
DOI : 10.1186/1471-2199-11-74
Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples, Experimental and Molecular Pathology, vol.92, issue.3, pp.275-280, 2012. ,
DOI : 10.1016/j.yexmp.2012.03.001
A V530I Mutation in c-KIT Exon 10 Is Associated to Imatinib Response in Extraabdominal Aggressive Fibromatosis, Sarcoma, vol.25, issue.18, supplement, p.458156, 2010. ,
DOI : 10.1007/s00280-009-1010-0
Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT, British Journal of Dermatology, vol.22, pp.1160-1169, 2008. ,
DOI : 10.1111/j.1365-2133.2008.08827.x
Association of adult mastocytosis with M541L in the transmembrane domain of KIT, Journal of the European Academy of Dermatology and Venereology, vol.32, pp.1118-1119, 2010. ,
DOI : 10.1111/j.1468-3083.2010.03599.x
Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia ??? potential clinical significance, Leukemia, vol.16, issue.2, pp.170-177, 2002. ,
DOI : 10.1038/sj.leu.2402341
The c-kit (CD117) sequence variation M541L, but not N564K, is frequent in the general population, and is not associated with CML in Caucasians, Leukemia, vol.12, issue.2, pp.354-355, 2006. ,
DOI : 10.1038/sj.leu.2404038
The prevalence of the c-kit exon 10 variant, M541L, in aggressive fibromatosis does not differ from the general population, Journal of Clinical Pathology, vol.64, issue.11, pp.1021-1024, 2011. ,
DOI : 10.1136/jcp.2011.090498
Impact of KIT exon 10 M541L allelic variant on the response to imatinib in aggressive fibromatosis: analysis of the desminib series by competitive allele specific Taqman PCR technology, BMC Cancer, vol.64, issue.Suppl 10, p.632, 2014. ,
DOI : 10.1136/jcp.2011.090498
URL : https://hal.archives-ouvertes.fr/inserm-01097447